Preliminary results of the INSPIRE trial with the novel MGuard™ stent system containing a protection net to prevent distal embolization

Maia, Felipe; Costa, J. Ribamar; Abizaid, Alexandre; Feres, Fausto; Costa, Ricardo; Staico, Rodolfo; Siqueira, Dimytri; Esteves, Vinícius; Sousa, A; Sousa, J. Eduardo

doi:10.1002/ccd.22473

Cited by 35 publications

(13 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The primary endpoint of 30‐day efficacy has been published elsewhere [8]. In brief, all patients were successfully submitted to MGuard stent implantation with no major adverse event (cardiac death, MI, and target‐lersion revascularization) up to 1 month of follow‐up.…”

Section: Resultsmentioning

confidence: 99%

One‐year results of the INSPIRE trial with the novel MGuard stent: Serial analysis with QCA and IVUS

Costa

Abizaid

Feres

et al. 2011

Cathet Cardio Intervent

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

One‐year results of the INSPIRE trial with the novel MGuard stent: Serial analysis with QCA and IVUS

Costa

Abizaid

Feres

et al. 2011

Cathet Cardio Intervent

Self Cite

View full text Add to dashboard Cite

show abstract

“…In addition to embolic protection, the MGuard net diffuses strut pressure which might minimise injury to the vessel wall and reduce restenosis. Preliminary results with this stent demonstrated favourable early performance in a study that included 16 patients who underwent SVG PCI with no angiographic/procedural complications, and no adverse events up to 30 days 39. This strategy seems to be a promising approach, but it needs further validations in a large randomised trial.…”

Section: Pci Of Svgmentioning

confidence: 97%

An update on coronary bypass graft intervention

Dash

2014

Heart Asia

View full text Add to dashboard Cite

Coronary artery bypass grafting (CABG) remains one of the most common surgical procedures. In spite of great advancements like arterial grafts and off-pump bypass procedure, recurrent ischaemia may ensue with the lesions of the graft. Early postoperative ischaemia (<30 days) is due to graft occlusion or stenosis, and percutaneous coronary intervention (PCI) is frequently feasible. Late postoperative ischaemia (>3 years) is most often due to a saphenous vein graft (SVG) lesion. Multiple diseased grafts, reduced left ventricular function, and available arterial conduits favour repeat CABG, whereas, a patent left internal mammary artery to left anterior descending favours PCI. Embolic protection reduces atheroembolic myocardial infarction during PCI of SVG and should be routinely used in treatment of SVG lesions. A variety of vasodilators may reduce the risk of or mitigate the consequences of noreflow. Drug-eluting stents reduce restenosis in SVG grafts, and have become the default strategy for many interventionalists.

show abstract

“…The MGuard stent was successfully implanted in all cases, and final TIMI grade 3 flow was achieved in all patients. There was no case of distal embolization during angioplasty [23]. At 6 months, routine control angiography was performed in all cases …”

Section: Clinical Profile and Postmarketing Findingsmentioning

confidence: 99%

Evidence for mesh-covered stent implantation in ST-segment elevation myocardial infarction

Dziewierz¹,

Dudek²

2011

Interventional Cardiology

View full text Add to dashboard Cite

Primary percutaneous coronary intervention for acute myocardial infarction offers the highest effectiveness in achieving patency of the infarct-related artery. However, the presence of normal coronary flow in the infarct-related artery does not always translate into the restoration of myocardial perfusion through cardiac microcirculation. Several pharmacological agents, as well as mechanical devices (i.e., aspiration catheters, mechanical thrombectomy, distal protection devices) were introduced in recent years to reduce the risk of distal embolization during primary percutaneous coronary intervention and to improve myocardial reperfusion. Recently, a new device has been introduced in the market, aiming to protect microcirculation: the MGuard™ stent (InspireMD, Tel Aviv, Israel), a bare-metal stent covered by micronlevel mesh, which prevents distal embolization by blocking the prolapse of thrombi through the stent struts during deployment. This article discusses data concerning safety and efficacy of mesh-covered stent implantation in an ST-segment elevation myocardial infarction setting.KEYWORDS: embolization n mesh n myocardial infarction n primary angioplasty n stent n thrombus

show abstract

Preliminary results of the INSPIRE trial with the novel MGuard™ stent system containing a protection net to prevent distal embolization

Abstract: In this preliminary evaluation, the MGuard device demonstrated excellent performance in a highly complex lesion subset, including absence of angiographic/procedural complications, and no adverse events up to 30-day FU.

Cited by 35 publications

References 23 publications

One‐year results of the INSPIRE trial with the novel MGuard stent: Serial analysis with QCA and IVUS

One‐year results of the INSPIRE trial with the novel MGuard stent: Serial analysis with QCA and IVUS

An update on coronary bypass graft intervention

Evidence for mesh-covered stent implantation in ST-segment elevation myocardial infarction

Contact Info

Product

Resources

About